Eighty-five subjects with symptomatic primary (P) human immunodeficiency virus (HIV) type 1 infection were analyzed in a retrospective cohort study to investigate the long-term clinical benefit of antiretroviral treatment during PHIV infection. Zidovudine treatment was initiated (PHIV treatment group) in 21 persons a median of 9 days after onset of PHIV symptoms and continued for a median of 55 days (range, 21-99). Sixty-four subjects did not receive early antiretroviral treatment (PHIV nontreatment group). After follow-up for 3-10 years, 33 subjects had developed AIDS and 22 subjects had died of AIDS. The median times for progression to AIDS and death were 6.4 and 9
Primary (P) human immunodeficiency virus (HIV) type 1 infection is associated with extremely high levels of plasma HIV RNA, and immediate initiation of antiretroviral treatment is generally recommended [1] . Treatment of PHIV infection using combinations of antiretroviral drugs has, however, been evaluated only during short-term follow-up in a limited number of cases [2] [3] [4] . Zidovudine therapy initiated during PHIV infection has been reported in three studies.
In a study reported in 1991, 11 subjects were treated with 1000 mg of zidovudine daily for a median of 56 days [5] , but in comparison with untreated historical controls, no significant difference in disease progression was found [6] . In 1995, treatment with 500 mg of zidovudine a day was compared with placebo in 77 patients with PHIV infection [7] , and in 1998, in another study, 28 patients were randomized to 1000 mg of zidovuine daily or placebo for 24 weeks [8] . In both studies, zidovudine treatment resulted in higher CD4 ϩ cell counts but not in a significant reduction in plasma virus load. One of the studies also recorded fewer minor opportunistic infections in the zidovudine arm during 15 months of follow-up [7] .
To investigate whether very early zidovudine treatment of HIV infection is associated with long-term clinical benefit, we recorded development of AIDS and survival for 3-10 years in Study patients. Clinical data on PHIV patients have been recorded in databases since about 1985 at both study sites. From these databases, we selected all subjects with symptomatic PHIV infection between 1 January 1987 and 31 December 1993 and assigned them to either the PHIV treatment group (if they received zidovudine monotherapy within 6 weeks after onset of symptoms) or as controls, if not given such treatment (PHIV nontreatment group). All included subjects had experienced a seroconversion illness of acute onset. In each case, seroconversion was determined by a negative HIV antibody sample followed by a positive sample. Antiretroviral treatment was offered to patients with PHIV infection according to clinical practice at the study sites at the time of diagnosis. Zidovudine became available in 1987, and between 1987 and 1990, patients were offered zidovudine treatment because of ongoing pilot studies at the study sites. In general, zidovudine treatment was for 6 weeks in accordance with common recommendations for occupational postexposure prophylaxis, but the duration of treatment was determined by the individual physician and the patient in each case. Both treated and untreated patients were seen regularly at 3-to 6-month intervals during follow-up. Antiretroviral therapy and prophylactic treatments for opportunistic infections were offered in accordance with common clinical practice at the time.
Patients and Methods

Study
Definitions and statistical analysis. Two definite markers of To compare the antiretroviral treatment regimen during followup (from 6 weeks after onset of PHIV and later), subjects were classified into 3 categories: no antiretroviral treatment, only nucleoside analogue reverse transcriptase inhibitor treatment (treatment with either one or several drugs-zidovudine, didanosine, zalcitabine, stavudine, or lamivudine), or protease inhibitor-containing treatment (treatment with either one or several drugs-saquinavir, indinavir, ritonavir, or nelfinavir).
Differences between study groups were assessed by using Student's t test for continuous variables and by x 2 test or Fisher's exact test for categorical variables. Tests for difference in survival were done separately for the two end points using the survival analysis module of the JMP program (SAS Institute, Cary, NC) for Macintosh. The Wilcoxon test was used to determine the significance of differences in survival between the two groups. The date of onset of symptoms of PHIV was used as the start point for infection in the survival analysis. Two-sided P values !.05 were considered significant.
Data on patients were censored at the last visit of patients thereafter lost to follow-up, at the time of death in cases of death from non-HIV-related causes, and at the end of the study (31 December 1996) for those who were still alive and being followed at that point.
Results
PHIV infection.
Altogether 85 subjects had experienced a symptomatic PHIV infection, and 21 of these had been treated with zidovudine (PHIV treatment group); 64 subjects were not treated (PHIV nontreatment group). The median months for onset of symptoms of PHIV infection were October 1989 (PHIV treatment group) and July 1990 (PHIV nontreatment group). Baseline characteristics are shown in table 1. There were no significant differences between the two groups in age, sex, or transmission category. Zidovudine treatment was initiated a median of 9 days (range, 1-42) after onset of symptoms of PHIV infection with a median dose of 1000 mg (range, 600-1200) daily. One subject discontinued zidovudine treatment after 6 days due to toxicity; the others were treated for a median of 55 days (range, 21-99).
Follow-up. There were no significant differences between the two groups in the proportion of patients receiving primary Pneumocystis carinii pneumonia prophylaxis ( ), anti-P ϭ .81 retroviral treatment ( ), or type of antiretroviral treat-P ϭ .36 ment regimen ( ) during the follow-up period. The mean P ϭ .62 duration of treatment with protease inhibitors for 5 of 21 subjects in the PHIV treatment group and for 15 of 64 subjects in the PHIV nontreatment group were 6.6 and 6.9 months, respectively ( ). P ϭ .89
The rates of progression to AIDS and to death from AIDS between Sydney and Stockholm were not different ( for P 1 .10 both). During follow-up, 33 subjects developed AIDS-defining conditions, and 22 subjects died of AIDS. The median time for progression to AIDS and to death from AIDS in all 85 patients were 6.4 and 9.1 years, respectively, as determined by life table estimate analysis.
In the PHIV treatment group, 1 subject was lost to followup and 9 progressed to AIDS, of whom 4 died. Sixteen subjects were still being followed after a mean of 6.6 years. In the PHIV nontreatment group, 5 subjects were lost to follow-up, and 18 subjects died of AIDS. After a mean of 4.8 years, 41 subjects continued to be followed, 6 of whom had developed AIDSdefining conditions. No patients in either group died of non-HIV-related causes.
Comparison of disease progression. Progression rates to AIDS and to death from AIDS did not differ significantly between the PHIV treatment and nontreatment groups, as shown in figure 1 ( and , respectively). When we cen-P ϭ .21 P ϭ .13 sored all data at 31 December 1995 instead of 31 December 1996, thereby reducing the number of persons who had received protease inhibitor treatment from 20 to 3, the results comparing the progression rates for the two end points were not changed ( and , respectively). P ϭ .25 P ϭ .13
Discussion
The present study constitutes one of the largest cohorts described so far with long-term follow-up after symptomatic PHIV infection. The previously reported poor long-term out- come of these patients, compared with patients seroconverting without symptoms [9] , is verified: Half of the patients in this series were estimated to have developed AIDS-defining conditions 6.4 years after symptomatic seroconversion, in contrast to the ∼10 years reported in several cohorts of homosexual men recruited regardless of whether they had a clinical illness at seroconversion [10] .
We could not demonstrate any improvement in prognosis for the persons given zidovudine during PHIV infection. There may be several possible explanations for this. Because this study was not randomized, the subjects may have been selected for treatment because of a more severe primary illness. Some reports indicate that fever for 12 weeks during primary infection is correlated with subsequent accelerated disease progression [11] . However, a selection for treatment on the basis of a long-lasting PHIV infection was unlikely in the majority of cases, as the median day for start of treatment in our study was day 9 after onset of symptoms. Moreover, we found no differences between the two groups when using a scoring system for severity of symptoms and days of hospitalization during PHIV infection (data not shown).
The length of treatment in the present study was in accordance with then available recommendations for occupational postexposure prophylaxis. The median treatment was 55 days, in comparison with 6 months in the two previously reported studies [7, 8] . It is possible that a longer course of treatment might have a beneficial effect on long-term clinical outcome.
The prognosis of the study patients may also be influenced during the follow-up period. Treatment with combinations of antiretroviral drugs, especially the inclusion of a protease inhibitor, has been shown to significantly improve clinical outcome [12] and thereby may compensate for prognostic differences in PHIV. In the present study, the proportion of patients treated with a combination regimen was equal in both groups studied and, furthermore, an exclusion of all follow-up data after 31 December 1995 to reduce the potential effect of disparate protease inhibitor use did not significantly change the results.
Although possible errors of study design were considered, an association between early zidovudine treatment and improved long-term outcome could not be detected. The obvious explanation for the lack of long-term clinical benefit in the present study would be the relatively weak and, because of the emergence of drug-resistant HIV variants, transient antiretroviral effect of zidovudine given as monotherapy. The European-Australian PHIV study [7] reported a reduced risk of developing minor opportunistic infections for zidovudine-treated subjects during a 15-month follow-up period, which is in accordance with other studies reporting an early but transient clinical benefit of zidovudine given as monotherapy to HIV-infected persons in asymptomatic stages after PHIV infection [13] . New data on HIV pathogenesis and the detection of extremely high concentrations of plasma HIV RNA in samples drawn from patients during PHIV infection, in most cases 1-cop-6 50 ϫ 10 ies/mL [3] , provides strong theoretical support for early intervention using a more aggressive regimen than zidovudine monotherapy.
It has been suggested that potent therapy for many years may eventually eradicate all virus from an infected person. The best opportunity for eradication of HIV, if possible at all, may be when treatment is initiated at PHIV infection. Such treatment may reduce the early dissemination of virus throughout the body, decrease the pool of latently infected cells, and preserve immune function intact.
Rosenberg et al. [14] reported that persons treated with potent antiretroviral therapy during PHIV infection develop and maintain a vigorous HIV-1-specific CD4 ϩ T cell response, which is not seen after initiation of the same treatment in chronic HIV infection [15] and is rarely found in untreated persons, except in some long-term nonprogressors. This report may indicate that even if the ultimate goal of eradication is not reached, initiation of treatment during symptomatic primary HIV infection still may transform these persons with an otherwise highly accelerated disease progression into long-term nonprogressors.
